Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study

Abstract

Researchers worldwide with information about the Kirsten ras (Ki-ras) tumour genotype and outcome of patients with colorectal cancer were invited to provide that data in a schematized format for inclusion in a collaborative database called RASCAL (The Kirsten ras in-colorectal-cancer collaborative group). Our results from 2721 such patients have been presented previously and for the first time in any common cancer, showed conclusively that different gene mutations have different impacts on outcome, even when the mutations occur at the same site on the genome. To explore the effect of Ki-ras mutations at different stages of colorectal cancer, more patients were recruited to the database, which was reanalysed when information on 4268 patients from 42 centres in 21 countries had been entered. After predetermined exclusion criteria were applied, data on 3439 patients were entered into a multivariate analysis. This found that of the 12 possible mutations on codons 12 and 13 of Kirsten ras, only one mutation on codon 12, glycine to valine, found in 8.6% of all patients, had a statistically significant impact on failure-free survival (P = 0.004, HR 1.3) and overall survival (P = 0.008, HR 1.29). This mutation appeared to have a greater impact on outcome in Dukes' C cancers (failure-free survival, P = 0.008, HR 1.5; overall survival P = 0.02, HR 1.45) than in Dukes' B tumours (failure-free survival, P = 0.46, HR 1.12; overall survival P = 0.36, HR 1.15). Ki-ras mutations may occur early in the development of pre-cancerous adenomas in the colon and rectum. However, this collaborative study suggests that not only is the presence of a codon 12 glycine to valine mutation important for cancer progression but also that it may predispose to more aggressive biological behaviour in patients with advanced colorectal cancer.

Cited by papers we hold 13

• Pathological Features and Prognostication in Colorectal Cancer · 2021
  No notice
• Prognostic and Predictive Molecular Biomarkers for Colorectal Cancer: Updates and Challenges · 2020
  No notice
• Exosomal circRNAs: biogenesis, effect and application in human diseases · 2019
  No notice
• The Developing Story of Predictive Biomarkers in Colorectal Cancer · 2019
  No notice
• Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance · 2015
  No notice
• Colorectal Cancer Biomarkers: Where Are We Now? · 2015
  No notice
• Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review · 2014
  No notice
• Differences in Survival between Colon and Rectal Cancer from SEER Data · 2013
  No notice
• Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer · 2012
  No notice
• Prognostic and Predictive Roles of KRAS Mutation in Colorectal Cancer · 2012
  No notice
• EGFR Signaling in Colorectal Carcinoma · 2011
  No notice
• Activating K-Ras mutations outwith ‘hotspot’ codons in sporadic colorectal tumours – implications for personalised cancer medicine · 2010
  No notice
• KRAS Mutations in Primary Colorectal Cancer Tumors and Related Metastases: A Potential Role in Prediction of Lung Metastasis · 2009
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.